Speaker Short Biography
-
Li Xing
CEO
LexBio Therapeutics
Short Biography
Dr. Xing has nearly thirty years’ industrial experience in pharmaceutical research. Previously at WuXi AppTec in Boston, she built the AI drug discovery function from ground up. Prior to joining WuXi she was a principal investigator at Pfizer for more than fifteen years, where she co-invented multiple clinical candidates and supervised postdoctoral researchers. Dr. Xing has published more than a hundred peer-reviewed journal articles and international patents, including thirty US granted patents. She received her Ph.D. in polymer science from University of Akron, and double bachelor’s degrees in solid state physics and computer technology from Tsinghua University.
Presentation Topic: AI accelerated drug discovery
LexBio employs the synergistic advantages of domain expertise and modern technology to accelerate early-stage drug discovery. Our deep learning (DL) centric AI platform integrates state-of-the-art machine learning solutions, high-end computing environment, and the user-friendly API to provide a digital laboratory for one-stop experimentation of predictive modeling and molecular generation. With such empowerment our discovery pipeline has grown to consist of projects in oncology, inflammation, and immunology. Two leading assets are advancing through IND-enabling studies, demonstrating superior in vitro and in vivo efficacies to the existing compounds, with the potential of becoming the first-line therapies for multiple solid tumors.
